Extensive failure of 3 main HIV drugs is slow in routine clinical practice

December 06, 2007

Extensive virological failure of the three main classes of HIV antiretroviral drugs occurs slowly in routine clinical practice. This finding is good news for the planning of treatment programmes in developing countries, where additional drugs outside these classes are unlikely to be available for some time. These are the conclusions of authors of an Article in this week's edition of The Lancet.

The three original main classes of HIV antiretroviral drugs are nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors. All these drugs work by suppressing HIV replication, so they are said to have failed when they lose their ability to suppress HIV viral load. Triple-class failure has generally been defined by virological failure of at least one drug in each of the three main classes, but more extensive failure is defined as extensive failure in all three classes. In developing countries, access to drugs will probably be restricted to the three original classes for years to come, so understanding the durability of the antiviral efficacy of these classes is crucial for long-term planning.

Professor Andrew Phillips, Royal Free and University College Medical School, London, UK, and colleagues used data from 7916 patients on from The UK Collaborative HIV Cohort Study (funded by the Medical Research Council) for their analysis. The average age of these patients was 36, and 25% of them were women. They had all started antiretroviral therapy with three or more drugs and were followed up for a maximum of 10 years (1405 patients were followed up for at least six years).

The researchers found that 167 patients developed extensive triple-class failure during follow up. The cumulative risk of triple-class failure was estimated at 9.2% by 10 years, with evidence that this rate has decreased by 14% per year in the time period covered. In these 167 patients, 101 (60%) subsequently had at least one viral load below 50 copies per ml, the lowest detectable level -- showing that the drugs retained some of the virological activity post-failure. At the time of extensive triple-class failure 90% of the 167 patients had virological failure of seven or more drugs. The risk of death by five years from the time of extensive triple-class failure was 10.6%.

The authors conclude: "Our study has shown that the rate at which patients starting antiretroviral therapy have extensive virological failure of the three main antiretroviral drug classes seems to be slow, especially in those with CD4-cell counts greater than 200 cells per Âμl at the start of therapy. Furthermore, there is evidence that the rate has decreased over time as drugs and experience with their use have improved...[this] is especially encouraging for developing countries where drug availability will probably be restricted to three original drug classes for some time."

In an accompanying Comment, Dr Edward Mills, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada, and Dr Jean B. Nachega, Bloomberg School of Public Health, Department of International Health, Johns Hopkins University, Baltimore, MD, USA, say: "Phillips and colleagues' study underscores the need for access to alternative, less toxic, and more affordable first-line, second-line, and now third-line antiretroviral drugs in developing countries....because HIV/AIDS will be with us for the foreseeable future, we need a visionary response that treats poor patients as optimally as wealthier patients. In years to come, we will look back and wonder if we can really say we did the best we could.">/p>
Professor Andrew Phillips, Royal Free and University College Medical School, London, UK. T) +44 (0) 20 7830 2886 / +44 (0) 7738 181457 E) a.phillips@pcps.ucl.ac.uk

Dr Jean B. Nachega, Bloomberg School of Public Health, Department of International Health, Johns Hopkins University, Baltimore, MD, USA, T) +1 410-955-2378 E) jnachega@jhsph.eduView the paper associated with this press release by clicking on the link below:



Related Drugs Articles from Brightsurf:

The danger of Z-drugs for dementia patients
Strong sleeping pills known as 'Z-drugs' are linked with an increased risk of falls, fractures and stroke among people with dementia, according to new research.

Wallflowers could lead to new drugs
Plant-derived chemicals called cardenolides - like digitoxin - have long been used to treat heart disease, and have shown potential as cancer therapies.

Bristol pioneers use of VR for designing new drugs
Researchers at the University of Bristol are pioneering the use of virtual reality (VR) as a tool to design the next generation of drug treatments.

Towards better anti-cancer drugs
The Bayreuth biochemist Dr. Claus-D. Kuhn and his research team have deciphered how the important human oncogene CDK8 is activated in cells of healthy individuals.

Separating drugs with MagLev
The composition of suspicious powders that may contain illicit drugs can be analyzed using a quick and simple method called magneto-Archimedes levitation (MagLev), according to a new study published in the journal Angewandte Chemie.

People are more likely to try drugs for the first time during the summer
American teenagers and adults are more likely to try illegal or recreational drugs for the first time in the summer, a new study shows.

Drugs used to enhance sexual experiences, especially in UK
Combining drugs with sex is common regardless of gender or sexual orientation, reveals new research by UCL and the Global Drug Survey into global trends of substance-linked sex.

Promising new drugs for old pathogen Mtb
UConn researchers are targeting a metabolic pathway, the dihydrofolate reductase pathway, crucial for amino acid synthesis to treat TB infections.

Can psychedelic drugs heal?
Many people think of psychedelics as relics from the hippie generation or something taken by ravers and music festival-goers, but they may one day be used to treat disorders ranging from social anxiety to depression, according to research presented at the annual convention of the American Psychological Association.

New uses for existing antiviral drugs
Broad-spectrum antiviral drugs work against a range of viral diseases, but developing them can be costly and time consuming.

Read More: Drugs News and Drugs Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.